Overview
CJC-1295 + Ipamorelin Blend is a research-grade peptide used primarily in laboratory settings to facilitate investigations into growth hormone release and related pathways. This blend combines CJC-1295, a GHRH analogue known for its long half-life of 6 to 8 days, with Ipamorelin, a selective GHRP analogue. Together, these compounds offer a unique profile for researchers focusing on the dynamics of growth hormone stimulation and regulation.
When you buy CJC-1295 + Ipamorelin Blend, you’re equipping your lab with a tool designed for serious research. The focus keyword, ‘buy CJC-1295 Ipamorelin blend research peptide,’ resonates with many researchers seeking reliable and effective compounds in their studies. CJC-1295 enhances the efficacy of Ipamorelin, creating a blend that can be pivotal for growth hormone research.
Key Features
- High-purity research-grade peptide.
- CJC-1295’s extended half-life allows for fewer dosing requirements.
- Ipamorelin’s selectivity can lead to targeted research outcomes.
- Available in convenient configurations for various research needs.
- Ideal for studies related to growth hormone effects.
Specifications
| Configuration | Amount |
|---|---|
| 5mg/5mg Blend | 5 mg |
| 10mg/10mg Blend | 10 mg |
| 5/5mg Blend Kit | 10 vials |
| 10/10mg Blend Kit | 10 vials |
FAQ
What is the purpose of the CJC-1295 + Ipamorelin Blend?
This blend is designed for laboratory research focusing on the mechanisms of growth hormone release and its physiological impacts.
How should I store the CJC-1295 + Ipamorelin Blend?
Store the peptide in a cool, dry place, and ensure it is protected from light. Follow specific storage recommendations for optimal stability.
Can I purchase this blend in bulk?
Yes, bulk purchases are available through our kits, which include multiple vials for larger-scale research projects.
Related Products
Browse more in Growth Hormone and Performance.
Always read the label and use products as directed. Consult a qualified professional where appropriate.



Reviews
There are no reviews yet.